China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug HSK21542, aimed at treating chronic pruritus.
Understanding the Impact of Chronic Pruritus
Pruritus, or itching, is an unpleasant sensation that triggers the urge to scratch. This condition not only affects the patient’s emotional well-being but also poses a risk of skin damage and infection due to repeated scratching, severely impacting the patient’s quality of life. The incidence rate of chronic pruritus is over 10% in adults and can reach as high as 60% in the elderly population. Current medications for pruritus are often either insufficiently effective or present safety concerns.
HSK21542: A Potential Breakthrough in Pruritus Treatment
HSK21542 is a selective peripheral Kappa receptor agonist that exhibits high selectivity and affinity. It works by synergistically regulating potassium and calcium currents with the involvement of G protein. The drug inhibits itching through the blockade of itching signal transduction and the inhibition of excitability in the dorsal root ganglion and peripheral sensory nerves. By reducing the release of inflammatory factors and neurotransmitters, HSK21542 has the potential to offer a more effective and safer treatment option for chronic pruritus.-Fineline Info & Tech
